Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.

Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X.

Arthritis Res Ther. 2012 Nov 19;14(6):R249. doi: 10.1186/ar4092.

2.

Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.

Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.

J Rheumatol. 2013 Oct;40(10):1650-7. doi: 10.3899/jrheum.121515. Epub 2013 Aug 15.

PMID:
23950185
3.

A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.

Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS.

Rheumatology (Oxford). 2009 Sep;48(9):1114-21. doi: 10.1093/rheumatology/kep155. Epub 2009 Jul 9. Review.

4.

A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study.

Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF.

Ann Rheum Dis. 2010 Jul;69(7):1333-7. doi: 10.1136/ard.2009.121160. Epub 2010 May 24.

PMID:
20498212
5.

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.

Granger B, Combe B, Le Loet X, Saraux A, Guillemin F, Fautrel B.

RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016.

6.

Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.

Ellingsen T, Hansen I, Thorsen J, Møller BK, Tarp U, Lottenburger T, Andersen LS, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Lindegaard H, Jacobsen S, Østergaard M, Vestergaard A, Jurik AG, Junker P, Christensen AF, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K.

Scand J Rheumatol. 2014;43(2):91-100. doi: 10.3109/03009742.2013.803149. Epub 2013 Aug 28.

PMID:
23980529
7.

Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.

van Nies JA, Tsonaka R, Gaujoux-Viala C, Fautrel B, van der Helm-van Mil AH.

Ann Rheum Dis. 2015 May;74(5):806-12. doi: 10.1136/annrheumdis-2014-206047. Epub 2015 Jan 5.

PMID:
25561360
8.

Association of tobacco exposure and reduction of radiographic progression in early rheumatoid arthritis: results from a French multicenter cohort.

Vesperini V, Lukas C, Fautrel B, Le Loet X, Rincheval N, Combe B.

Arthritis Care Res (Hoboken). 2013 Dec;65(12):1899-906. doi: 10.1002/acr.22057.

9.

Can we prevent rapid radiological progression in patients with early rheumatoid arthritis?

Heimans L, Wevers-deBoer KV, Ronday HK, Collée G, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF.

Clin Rheumatol. 2015 Jan;34(1):163-6. doi: 10.1007/s10067-014-2815-8. Epub 2014 Nov 29.

PMID:
25431327
10.

Prediction of radiographic damage in early arthritis by sonographic erosions and power Doppler signal: a longitudinal observational study.

Funck-Brentano T, Gandjbakhch F, Etchepare F, Jousse-Joulin S, Miquel A, Cyteval C, Lukas C, Tobón GJ, Saraux A, Boumier P, Goupille P, Bourgeois P, Fautrel B.

Arthritis Care Res (Hoboken). 2013 Jun;65(6):896-902. doi: 10.1002/acr.21912.

11.

Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.

Lillegraven S, Paynter N, Prince FH, Shadick NA, Haavardsholm EA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH.

Arthritis Care Res (Hoboken). 2013 Apr;65(4):526-33. doi: 10.1002/acr.21870.

12.

Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study.

Benbouazza K, Benchekroun B, Rkain H, Amine B, Bzami F, Benbrahim L, Atouf O, Essakalli M, Abouqal R, Dougados M, Hajjaj-Hassouni N.

BMC Musculoskelet Disord. 2011 Nov 23;12:266. doi: 10.1186/1471-2474-12-266.

13.

Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.

Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, Dougados M.

Ann Rheum Dis. 2015 Apr;74(4):724-9. doi: 10.1136/annrheumdis-2013-204178. Epub 2014 Jan 7.

PMID:
24399234
14.

Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort.

Degboé Y, Constantin A, Nigon D, Tobon G, Cornillet M, Schaeverbeke T, Chiocchia G, Nicaise-Roland P, Nogueira L, Serre G, Cantagrel A, Ruyssen-Witrand A.

RMD Open. 2015 Nov 26;1(1):e000180. doi: 10.1136/rmdopen-2015-000180. eCollection 2015.

16.

Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.

Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.

Scand J Rheumatol. 2009;38(4):240-5. doi: 10.1080/03009740802609566.

PMID:
19229766
17.

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.

Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.

Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29.

PMID:
21640044
18.

The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.

Mueller RB, Schiff M, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, von Kempis J; Swiss Clinical Quality Management (SCQM) physicians.

Clin Rheumatol. 2015 Jan;34(1):51-9. doi: 10.1007/s10067-014-2737-5. Epub 2014 Jul 15.

PMID:
25024096
19.

Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting.

Sanmarti R, Gomez A, Ercilla G, Gratacos J, Larrosa M, Suris X, Vinas O, Salvador G, Munoz-Gomez J, Canete JD.

Rheumatology (Oxford). 2003 Sep;42(9):1044-9. Epub 2003 Apr 16.

20.

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.

Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, Forslind K, van Vollenhoven RF; SWEFOT study group.

Ann Rheum Dis. 2015 Aug;74(8):1509-14. doi: 10.1136/annrheumdis-2013-204601. Epub 2014 Apr 4.

Items per page

Supplemental Content

Write to the Help Desk